HC Wainwright Reaffirms Buy Rating for PepGen (NASDAQ:PEPG)

HC Wainwright restated their buy rating on shares of PepGen (NASDAQ:PEPG) in a research report sent to investors on Friday morning,Benzinga reports. They currently have a $26.00 price target on the stock.

PEPG has been the subject of several other research reports. Wedbush reiterated an “outperform” rating and set a $20.00 target price on shares of PepGen in a research report on Wednesday, July 31st. Bank of America downgraded PepGen from a “buy” rating to a “neutral” rating and set a $12.00 price objective for the company. in a report on Wednesday, July 31st.

PepGen Trading Down 1.0 %

Shares of PEPG traded down $0.05 during mid-day trading on Friday, hitting $4.96. 10,607 shares of the company traded hands, compared to its average volume of 116,670. The business has a 50-day moving average of $8.49 and a 200 day moving average of $12.22. PepGen has a one year low of $3.81 and a one year high of $19.30. The stock has a market capitalization of $161.65 million, a price-to-earnings ratio of -1.68 and a beta of 1.76.

PepGen (NASDAQ:PEPG) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.15). As a group, analysts anticipate that PepGen will post -3.16 earnings per share for the current year.

Institutional Investors Weigh In On PepGen

Large investors have recently bought and sold shares of the company. Acadian Asset Management LLC bought a new position in shares of PepGen during the first quarter worth $30,000. Point72 DIFC Ltd acquired a new stake in PepGen during the 2nd quarter worth $42,000. Allspring Global Investments Holdings LLC bought a new position in PepGen during the third quarter worth about $95,000. Renaissance Technologies LLC bought a new position in PepGen during the second quarter worth about $192,000. Finally, Marshall Wace LLP acquired a new position in PepGen in the second quarter valued at about $196,000. Institutional investors own 58.01% of the company’s stock.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.